The senolytic drug ABT-263 (Navitoclax), which effectively depletes senescent CD4+ T cells, senescent B cells (CD19+CD11c+T-bet+), and Tfh cells, significantly reduced these populations in lupus-prone MRL/lpr mice. The gene discussed is CD19; the disease is systemic lupus erythematosus.